Edition:
United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

20.50USD
7 Dec 2016
Change (% chg)

-- (--)
Prev Close
$20.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
603,883
52-wk High
$43.63
52-wk Low
$16.40

Jensen, Peder 

Dr. Peder K. Jensen, M.D., is an Independent Director of Acorda Therapeutics, Inc., since April 19, 2011. Dr. Jensen is currently president of Bay Way Consultants, LLC, a consulting firm founded by Dr. Jensen in 2010 that advises pharmaceutical and biotechnology companies. Dr. Jensen’s experience includes over 20 years with Schering-Plough Corporation, a global pharmaceutical company, and then Merck & Co., Inc. after the merger of Schering-Plough with Merck in 2009. During his tenure at Schering-Plough/Merck, Dr. Jensen held a number of global senior research and development positions, including Vice President Clinical Research, SPRI, Executive Vice President Worldwide Drug Development, SPRI, and most recently Corporate Senior Vice President, and General Manager, R&D for Japan and Asia/Pacific from 2006 to 2010. Dr. Jensen has more than 24 years of global drug development experience across a variety of therapeutic areas, including neurology, cardiovascular, anti-infective, oncology and immunology. Over the course of his career, Dr. Jensen has been responsible for more than 40 new drug approvals worldwide, including in the U.S., Europe and Japan. Dr. Jensen also currently serves on the boards of directors of BioCryst Pharmaceuticals, Inc. and FivePrime Therapeutics. Dr. Jensen received his M.D. from the University of Copenhagen.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen

4,045,180

David Lawrence

1,204,120

Andrew Blight

1,484,560

Jane Wasman

2,334,280

Burkhard Blank

--

Andrew Hindman

5,167,670
As Of  30 Dec 2014